A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis.
A randomized, placebo-controlled crossover trial utilizing vaporized cannabis containing placebo and 6.7% and 2.9% delta-9-tetrahydrocannabinol (THC) was performed in 42 subjects with central neuropathic pain related to spinal cord injury and disease. Subjects received two administrations of the study medication in a 4-hour interval. Blood samples for pharmacokinetic evaluation were collected, and pain assessment tests were performed immediately after the second administration and 3 hours later. Pharmacokinetic data, although limited, were consistent with literature reports, namely dose-dependent increase in systemic exposure followed by rapid disappearance of THC. Dose-dependent improvement in pain score was evident across all pain scale elements. Using mixed model regression, an evaluation of the relationship between plasma concentrations of selected cannabinoids and percent change in items from the Neuropathic Pain Scale was conducted. Changes in the concentration of THC and its nonpsychotropic metabolite, 11-nor-9-carboxy-THC, were related to percent change from baseline of several descriptors (eg, itching, burning, and deep pain). However, given the large number of multiple comparisons, false-discovery-rate-adjusted P-values were not significant. Plans for future work are outlined to explore the relationship of plasma concentrations with the analgesic response to different cannabinoids. Such an appraisal of descriptors might contribute to the identification of distinct pathophysiologic mechanisms and, ultimately, the development of mechanism-based treatment approaches for neuropathic pain, a condition that remains difficult to treat.
VA Northern California Health Care System, Mather, CA; Department of Physical Medicine and Rehabilitation, University of California, Sacramento, CA.
Barth L
BL
Wilsey
Department of Psychiatry, University of California, San Diego, La Jolla, CA.
Reena
R
Deutsch
PharmaPolaris International, Davis, CA.
Emil
E
Samara
Department of Psychiatry, University of California, San Diego, La Jolla, CA.
Thomas D
TD
Marcotte
Chemistry and Drug Metabolism, IRP, National Institute on Drug Abuse, Baltimore, MD.
Allan J
AJ
Barnes
Chemistry and Drug Metabolism, IRP, National Institute on Drug Abuse, Baltimore, MD; University of Maryland School of Medicine, Baltimore, MD, USA.
Marilyn A
MA
Huestis
VA Northern California Health Care System, Mather, CA; Department of Physical Medicine and Rehabilitation, University of California, Sacramento, CA.
Danny
D
Le
analgesia; blood concentrations; cannabinoids; medical marijuana